期刊文献+

我院2006—2007年抗肿瘤药物用药分析 被引量:4

Analysis of Anticancer Drugs Used in Our Hospital During Period 2006—2007
下载PDF
导出
摘要 目的了解抗肿瘤药物的应用情况。方法采用限定日剂量法、销售金额排序法和用药频度(DDDs)分析法进行统计、分析。结果医院抗肿瘤药物用药金额略有上升;其他抗肿瘤药及辅助药和抗肿瘤植物药占有相当大的市场份额;多西他赛销售金额连续2年位居榜首,奥沙利铂由2006年销售榜的第3位跃居至2007年的第2位;连续2年DDDs最高的为三苯氧胺。结论抗肿瘤植物药、辅助治疗药、抗代谢药和抗肿瘤抗生素系抗肿瘤的主要用药,其销售金额与DDDs在用药管理中具有同等重要的地位;建议临床医师多选择疗效确切、不良反应少、价格便宜的国产抗肿瘤药物,为国家医保基金和患者减少负担。 Objective To analyze the situation of antineoplastic drugs used in our hospital. Methods According to the original data of Kingstar Winning Corporation THIS computer management system in our hospital, we used the daily dosage restrictions, the amount of sales sort of medication and defined daily dose (DDDs) method for statistical analysis. Results The amount of anticancer medication in our hospital increased slightly; and other anti-tumor drugs and adjuvant therapy drugs and anti-tumor botanic drugs occupied a certain market share; the sales of docetaxel placed the top in two consecutive years. Oxaliplatin leapt from the third place in 2006 sales list to the second place in 2007; in two consecutive years the highest DDDs was Tamoxifen. Conclusion The main anti-tumor drugs such as anti-tumor botanical drugs, adjuvant therapy drugs, anti- metabolism drugs and anti- tumor antibiotics, the amounts of their sales are as important as the frequency of medication in the medication management. Doctors are recommended to use the domestic anti- tumor drugs with best efficacy, light side effect and cheap price according to the guiding principles of anti- tumor clinical studies for lowering the treatment costs of National Health Insurance and patients.
出处 《中国药业》 CAS 2009年第3期37-38,共2页 China Pharmaceuticals
关键词 抗肿瘤药物 金额排序 用药频度 anticancer drug amount sort DDDs sort
  • 相关文献

参考文献4

二级参考文献65

  • 1管忠震,徐瑞华.奈达铂临床研究进展[J].中国肿瘤临床,2004,31(13):774-780. 被引量:176
  • 2丁晓霜.人参炔三醇抑制肿瘤细胞增殖、诱导细胞周期停止于G_2/M期[J].国外医学(中医中药分册),2004,26(1):42-43. 被引量:6
  • 3陈小义,徐瑞成,陈莉,钱进.蟾蜍灵对人胃癌细胞系MGc-803的细胞毒作用[J].中草药,2000,31(12):920-922. 被引量:39
  • 4李文钧,郑永兴.石墨炉原子吸收法测定体内顺铂[J].药物分析杂志,1989,9(2):82-85. 被引量:10
  • 5胡发明.奥沙利铂的不良反应和安全性[J].国外医药合成药·生化药·制剂分册,1999,20(3):184-185.
  • 6Richard H, Wilson, Tanya Lehky, et al.Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability[J] .J Clin Oncol,2002,20(7):1767 - 1774.
  • 7Adelsberger H,Quasthoff S,Grosskreutz J,et al.The chemotherapeutic oxaliplatin alters voltage-gated Na(+)channel kinetics on rat sensory neurons[J].Eur J Pharmacol,2000,406(1):25-32
  • 8Sarah Taieb, Louis Descos, Gilles Freyer, et al. Lhermitte sign and urinary retention-atypical presentation of oxaliplatin neurotoxicity in four patients[J]. Cancer, 2002,94(9) : 2434 - 2440.
  • 9Misset JL. Oxaliplatin in practice [ J ] . Br J Cancer, 1998, 77(Suppl 4):S4- S7.
  • 10Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin; a critical review[ J ] . Clin Cancer Res ,2000,6(4) : 1205 - 1218.

共引文献109

同被引文献24

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部